BioXcel Therapeutics (BTAI) risk factors, FY2025 10-K

Risks Related to Financial Position and Need for Additional Capital

1. 01We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern70% rewritten
2. 02We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business and to assess our future viability
3. 03We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability
4. 04Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis
5. 05We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternativesNew
6. 06Our Clinical Reprioritization and other workforce reductions may not achieve our intended outcome45% rewritten

Risks Related to the Discovery and Development of Product Candidates

1. 07We have limited experience in drug discovery and drug development
2. 08Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer’s disease
3. 09We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer’s disease and patients with schizophrenia and bipolar patients82% rewritten
4. 10submission and it is possible that the FDA may not consider our available data adequate to support the submission. Further, even if the FDA accepts the sNDA submission, there is no assurance that the FDA will approve our sNDA and authorize an expanded IGALMI ® ’s label to include the broader at-home patient populationNew
5. 11However, we have limited experience in drug development and commercialization, and our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize product candidates in one or more additional disease indicationsNew
6. 12Interim “top-line” and preliminary data from our clinical trials, that we announce or publish from time to time, may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
7. 13The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
8. 14Clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain outcome
9. 15We depend on enrollment and evaluation of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected
10. 16Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval
11. 17The discovery and development of product candidates based on EvolverAI, BioXcel LLC’s proprietary pharmaceutical discovery and development engine, and our AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value
12. 18Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
13. 19The Company’s AI platform and BioXcel LLC’s EvolverAI may fail to help us discover and develop additional potential product candidates
14. 20Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition
15. 21A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval91% rewritten
16. 22designated as Breakthrough Therapies by the FDA also receive the benefits associated with Fast Track designation, including the potential for rolling review of an NDANew
17. 23Although the FDA has approved IGALMI ® for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI ® and for any product candidates for which we obtain approval77% rewritten
18. 24or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization toolsNew
19. 25The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses80% rewritten
20. 26is currently limited to the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults to be self-administrated by patients under the supervision of a health care providerNew
21. 27Disruptions at the FDA and other government agencies caused by funding shortages or staffing reductions could prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business81% rewritten
22. 28We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business
23. 29Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business, results of operations and financial conditionNew
24. 30We may be subject to extensive regulations outside the U.S. and may not obtain marketing approvals for products in Europe and other jurisdictions87% rewritten
25. 31the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to countryNew
26. 32We may be unable to maintain sufficient clinical trial liability insurance

Risks Related to Commercialization of Our Product Candidates

1. 33If our products do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations
2. 34If our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products, which would cause our business to suffer
3. 35If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing IGALMI ® or any product candidate for which we may obtain regulatory approval
4. 36We operate in a highly competitive and rapidly changing industry
5. 37Although we obtained FDA approval for IGALMI ® , our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement
6. 38Health care reform measures could hinder or prevent our product candidates’ commercial success42% rewritten
7. 39regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain adequate coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay
8. 40if applicable, Medicare Part B. Failure to make necessary disclosures and/or to identify overpayments additionally could result in allegations against us under the Federal False Claims Act and other laws and regulations

Risks Related to Our Relationship with BioXcel LLC

1. 41Approval of commercial terms between us and BioXcel LLC does not preclude the possibility of stockholder litigation, including but not limited to derivative litigation nominally against BioXcel LLC and against its directors and officers and also against us and our directors and officers
2. 42We continue to depend on BioXcel LLC to provide us with certain services for our business87% rewritten
3. 43The management of and beneficial ownership in BioXcel LLC may create, or may create the appearance of, conflicts of interest
4. 44Any disputes that arise between us and BioXcel LLC with respect to our past and ongoing relationships could harm our business operations
5. 45BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with other AI platforms that we may utilize, including our own in-house proprietary platform

Risks Related to Our Reliance on Third Parties

1. 46We, or third-party manufacturers on whom we rely, including ARx, may be unable to successfully scale-up manufacturing of our product and product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing any approved products
2. 47Our failure to find third-party collaborators to assist or share in the costs of product development could materially harm our business, financial condition, and results of operations

Risks Related to Our Business and Industry

1. 48Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations62% rewritten
2. 49Our future success may depend on our ability to attract and retain qualified personnel, including consultants
3. 50We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business
4. 51We may acquire other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results
5. 52Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading
6. 53Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses
7. 54Data breaches or cyber-attacks could disrupt our business operations and information technology systems or those of third parties on which we rely, adversely impact our financial results, or result in the loss or exposure of confidential or sensitive product candidate, clinical trial, employee, or Company information
8. 55Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition
9. 56Increased scrutiny of and evolving expectations for environmental, social and governance (“ESG”) initiatives may impose additional costs or otherwise adversely impact our business
10. 57Our failure to successfully acquire, develop and market additional product candidates or approved drug products could impair our ability to grow
11. 58Our ability to use our net operating losses and tax credits to offset future taxable income and income tax liabilities may be limited21% rewritten

Risks Related to Our Intellectual Property

1. 59It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially86% rewritten
2. 60patent applications relating to our platform technologies covering methods of use and applications of the platform technologiesNew
3. 61Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 62If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business
5. 63If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved products or product candidates
6. 64We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
7. 65An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidate
8. 66We may not be able to enforce our intellectual property rights throughout the world
9. 67If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed
10. 68If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished
11. 69We may be subject to claims that our employees, consultants or independent contractors have misappropriated the intellectual property rights, including know-how or trade secrets of a third party
12. 70Our intellectual property may not be sufficient to protect our products from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal
13. 71Furthermore, limitations, or perceived limitations, in our intellectual property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable risk to commercialization of our products or future products
14. 72Intellectual property rights and enforcement may be less extensive in jurisdictions outside of the U.S.; thus, we may not be able to protect our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual property

Risks Related to Owning our Common Stock

1. 73The price of our common stock may fluctuate substantially
2. 74Future sales and issuances of our common stock, including common stock that may be sold following exercise of outstanding warrants, would result in additional dilution of the percentage ownership of our stockholders and could adversely impact the share price of our common stock50% rewritten
3. 75If we do not maintain compliance with the continued listing standards of the Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictionsNew
4. 76If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations
5. 77We are a “smaller reporting company” and are able to avail ourselves of reduced disclosure requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors22% rewritten
6. 78Our certificate of incorporation, our bylaws, and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline
7. 79Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management is required to devote substantial time to compliance matters
8. 80If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline
9. 81Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows61% rewritten
10. 82Additional indirect taxes in various jurisdictions could materially adversely affect our business, financial condition, results of operations, and prospects